Nucleix Lands €50K EU Grant to Develop EpiCheck Cancer Screening Tests | GenomeWeb

This story has been updated with additional information from Nucleix.


NEW YORK (GenomeWeb) – Israeli cancer diagnostics firm Nucleix has announced a €50,000 ($56,998) Horizon 2020 grant from the European Commission to support commercial development of lung and colorectal cancer screening products.

The Rehovot-based firm will use the funds to continue developing cancer screening tests based on its EpiCheck platform, which identifies DNA methylation patterns extracted from urine and blood samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.

Mar
23
Sponsored by
Personal Genome Diagnostics

This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.

Mar
28

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.